BERGENBIO ANNOUNCES FIRST PATIENT DOSED WITH BEMCENTINIB IN RELAPSED MALIGNANT PLEURAL MESOTHELIOMA INVESTIGATOR SPONSORED PHASE IIA STUDY
(WorldNews Environment)

BERGENBIO ANNOUNCES FIRST PATIENT DOSED WITH BEMCENTINIB IN RELAPSED MALIGNANT PLEURAL MESOTHELIOMA INVESTIGATOR SPONSORED PHASE IIA STUDY Bergen, Norway, 7 October 2020 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that the first patient has been dosed and continues on therapy in a trial assessing bemcentinib in relapsed malignant mesothelioma patients, sponsored by the University of Leicester. With the support of the British Lung Foundation, which has provided £2.5 million in funding, the University of Leicester is leading the development of the world`s first molecularly...